In direct compression operations for veterinary oral solid dosage forms, ofloxacin API conforming to Ph. Eur. monograph 1455 or USP 43–NF 38 is not introduced as a freely flowing powder; lot-specific particle size distribution and low bulk density require a pre-blending step with a porous silica flow aid at 0.25 wt% to 0.75 wt% before dry addition to microcrystalline cellulose. The formulation is constrained by the fluoroquinolone carboxylate and tertiary amine moieties, which make the drug sensitive to alkaline hydrolysis and to chelation with polyvalent cations. Tablet blends are therefore prepared without calcium phosphate diluents, without aluminium silicate glidants above 0.5 wt%, and without magnesium stearate above 0.5 wt%; higher stearate film thickness retards disintegration below 15 minutes in water at 37°C when tested by the USP 701 method. On a rotary press fitted with 10 mm round tooling and a compression force of 8 kN to 12 kN, tablet hardness is maintained between 60 N and 90 N to avoid lamination from elastic recovery. Friability is kept below 1.0% after 100 revolutions in the USP 1216 apparatus, and dissolution is run in 900 mL of 0.1 M hydrochloric acid using USP apparatus 2 at 50 rpm, with NLT 80% released in 30 minutes. Capsule formulations frequently use dry granulation by roller compaction when the API fraction exceeds 40 wt%, because direct blend segregation at hopper transfer lines is observed as a top-to-bottom assay drift above 3% relative standard deviation. The granule fraction is milled through a 1.0 mm screen and blended with crospovidone 2.0 wt% as disintegrant; final loss on drying is held below 1.5% because residual moisture above 2.0% accelerates hydrolytic degradation of the piperazinyl ring during accelerated stability storage at 40°C/75% RH. Packaging with HDPE bottles and desiccant canisters is required where climatic Zone IVb exposure exceeds 30°C/75% RH for more than 3 months, and child-resistant closures follow ISO 8317:2015 where companion-animal labelling requires accidental ingestion protection. Published data for binary ofloxacin-silica blends at commercial scale are limited; the silica percentage is therefore verified by a six-lot process qualification on the specific paddle mixer geometry used.

What Limits the Autoclave Hold Time for Ofloxacin Veterinary Injections?

Terminal sterilisation of ofloxacin parenterals is governed less by thermal degradation of the fluoroquinolone nucleus than by pH shift and metal-catalysed oxidation. Aqueous solutions for intramuscular or subcutaneous injection are typically prepared at 2 mg/mL to 5 mg/mL, acidified with hydrochloric acid to pH 3.8–4.5, and stabilised with disodium edetate at 0.01% w/v to sequester trace iron leached from transfer pipework. The maximum autoclave hold time at 121°C should not exceed 15 minutes when the solution pH is above 5.0, because the zwitterionic species precipitates as a low-solubility aggregate after buffer addition with sodium citrate; this boundary is confirmed by subvisible particle counts rising above 25 particles per mL in the 10 µm channel when measured by light obscuration according to Ph. Eur. 2.9.19. Vials are filled under nitrogen overlay with residual oxygen below 0.5% in the headspace, and the final container is a Type I borosilicate glass ampoule or a rubber-stoppered vial with an ETFE-coated stopper to reduce leachable barium and zinc ions. Production-scale experience in a 300 L stainless-steel batch typically shows a critical hold time of 8 minutes at 121°C after steam penetration, and batch rejection occurs when the spore biological indicator for Geobacillus stearothermophilus has a population greater than 10⁶ CFU per unit because the final F₀ falls below 8 minutes. Degradation control is exercised by HPLC quantification under Ph. Eur. 2.2.29 or equivalent; the total unspecified impurity limit is typically 0.5% and the single highest impurity must remain below 0.3%. The injection is protected from UV and daylight throughout compounding, storage, and secondary packaging by amber glass and cartons; photodegradation products include demethylated and N-oxide derivatives that can form at 2000 lux/m² within 24 hours if unprotected.

For medicated feed incorporation, ofloxacin is first converted to a 10% w/w active premix by adsorption onto a carrier such as ground oat hulls or lactose monohydrate, using a ribbon mixer with a working capacity of 500 kg and a mixing time of 10 minutes after API addition. The premix is then diluted at 1.0 kg to 5.0 kg per ton of finished feed, which corresponds to active concentrations between 100 g/ton and 500 g/ton; the exact licensed dose and withdrawal period must follow the specific national veterinary marketing authorisation. Multi-ton feed manufacturing lines require the premix to be added after steam preconditioning when molasses or lignosulfonate binders are present, because those components can form reducing species at pellet die temperatures above 75°C. Conditioned mash is maintained at 75°C to 85°C for no more than 30 seconds before pelleting; above 85°C, darkening of lactose-based carriers occurs and the physical recovery of fine premix particles drops. Carriers containing calcium carbonate above 30% w/w, bentonite, kaolin, or zeolite above 2% w/w are excluded because fluoroquinolone carboxylate groups coordinate with aluminium, iron, calcium, and magnesium in the feed matrix. Batch-to-batch variance in premix assay is controlled through a two-stage sampling plan; in a 2,000 kg horizontal mixer, the CV of assay across 10 sampling points should not exceed 5% for the preblend and 10% for the finished feed. Published data for this specific configuration is limited, so the conditioning limit is set by the premix manufacturer’s stability validation rather than a compendial specification.

When Granulation Binder Viscosity Must Not Exceed 350 mPa·s

High-shear wet granulation of ofloxacin with povidone K30 binder is used for high-dose veterinary bolus and tablet formulations; the binder is prepared as a 5% w/w aqueous solution and its viscosity at 25°C must not exceed 350 mPa·s. Above that threshold, spray nozzle blockage and uneven binder distribution produce granules with a broad particle size distribution, and fines below 75 µm fall to the bottom of the fluid-bed dryer bowl, creating dry caking at the distributor plate. The granulation endpoint is controlled by impeller torque rather than time; a torque increase of 20% to 30% over baseline is usually sufficient to form agglomerates with a D50 of 150 µm to 250 µm in a top-drive high-shear granulator. Drying is carried out at inlet air temperature 50°C to 60°C in a fluidised bed, with final LOD 1.0%–2.0%; higher residual moisture causes tablet capping at compression forces above 10 kN. The dried granules are blended with croscarmellose sodium 2.0%–3.0% and compressed into immediate-release matrices; hypromellose K100M is avoided because it increases gel viscosity and retards release below the NLT 80% threshold in 30 minutes when tested in 900 mL of 0.1 M hydrochloric acid at 50 rpm. For capsule filling, the granule particle size must be kept below 30% retained on a 1.0 mm sieve to maintain fill weight variation under 4% on a 6,000 capsules/h dosing-disc machine. The final granules are stored in closed stainless-steel bins at 25°C and 35% RH for no more than 14 days before compression; longer storage increases moisture uptake and causes dissolution slowdown due to surface recrystallisation of the zwitterion.

Drinking Water Soluble Powder Dispersion and Hard Water Complexation Boundaries

In drinking water medication systems, soluble powder presentations intended for poultry or swine are formulated with an organic acid buffer, typically citric acid or malic acid, to hold the reconstituted water at pH 4.0–4.5 and to shift ofloxacin toward the protonated, more water-soluble species. Hard water with total hardness above 120 mg/L as CaCO₃ and bicarbonate alkalinity above 200 mg/L is a documented failure mode; dissolved calcium and magnesium form partially insoluble chelates with the fluoroquinolone 3-carboxylate group, producing visible turbidity and a drop in dissolved active content below 90% of label within 2 hours. In a 1,000 L proportioner tank fitted with a paddle stirrer at 200 rpm, the powder is added to the vortex rather than to standing water, and mixing is continued for 10 minutes. The solution is dispensed through a medicator set to 1% to 5% injection ratio; in-line 50 µm filters are not placed after the proportioner because fluoroquinolone precipitates accumulate at stagnant low-pH zones and reduce flow rate. Oxidative degradation is accelerated when free chlorine residual exceeds 2 mg/L; therefore water is drawn from a bypass after activated carbon treatment or allowed to degas for 12 hours before reconstitution. The made-up solution has a limited-use period of 24 hours at ambient temperatures up to 30°C and 48 hours at 2°C–8°C in closed light-protected stainless steel tanks; beyond this, pH-dependent degradation products begin to exceed 0.5% of the parent peak by HPLC. The dry powder itself is packaged in foil-lined polyethylene bags with moisture vapour transmission rate below 0.1 g/m²/day at 38°C/90% RH; if the package is reclosed poorly, the acidifier deliquesces and the ofloxacin becomes sticky and non-dispersible.

Otic solutions require a sterile aqueous vehicle rather than an oil-based vehicle; ofloxacin is dissolved at 0.3% w/v, preserved with benzalkonium chloride 0.01% w/v and adjusted to pH 5.0 with sodium hydroxide. The solution is not autoclaved after filling; it is sterilised by filtration through a 0.22 µm PVDF membrane, and integrity is tested with bubble-point method before and after filtration. The vehicle may contain hypromellose E4M at 0.2% w/v to increase otic residence time; higher viscosity grades are avoided because they produce an objectionable sticky residue on the pinna of dogs and cats. The formulation is filled into opaque LDPE dropper bottles with a 10 mL fill volume and a dropper tip that must not contain zinc stearate or aluminium oxide mold-release residues, because these polyvalent cations can precipitate the drug at the nozzle opening. Storage is controlled at 25°C or below; intermittent refrigeration at 2°C–8°C is acceptable, but freeze-thaw cycles are not, because crystal growth of benzalkonium chloride and ofloxacin occurs below 0°C. Oral liquid presentations for companion animals follow a similar pH and chelation boundary; they are prepared without sorbitol above 20% w/v because the aldehyde impurities in some sorbitol batches accelerate degradation of the piperazinyl side chain. Both solution types are protected from light in closed secondary cartons; unprotected storage under cool-white fluorescent light at 1,200 lux for 24 hours can generate the N-oxide derivative at levels exceeding 0.2% in amber-free clear bottles.